



**Condensed Financial Statement And Dividend Announcement For The Year Ended 31 December 2021**

**1(a) Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income**

	Note	Group					
		Fourth Quarter			Year-To-Date		
		Q4 2021 \$'000	Q4 2020 \$'000	Change %	31/12/2021 \$'000	31/12/2020 \$'000	Change %
<b>Revenue</b>							
Dental and Medical Clinics		43,595	40,801	7	160,211	126,378	27
Medical Laboratory and Dental Equipment & Supplies		9,699	3,021	221	45,388	11,242	304
<b>Total Revenue</b>	3	<b>53,294</b>	<b>43,822</b>	22	<b>205,599</b>	<b>137,620</b>	49
<b>Other Items of Income</b>							
Interest Income		6	27	(78)	11	278	(96)
<b>Other Items of Expense</b>							
Consumables and Supplies Used in Dental & Medical Clinics		(3,606)	(3,695)	(2)	(14,197)	(10,778)	32
Cost of Sales - Medical Laboratory and Dental Equipment & Supplies		(4,655)	(1,540)	202	(16,680)	(6,117)	173
Employee Benefits Expense		(30,208)	(24,762)	22	(102,989)	(75,915)	36
Depreciation and Amortisation Expense		(1,109)	(893)	24	(4,134)	(3,458)	20
Depreciation of Right-Of-Use Assets		(1,630)	(2,689)	(39)	(9,456)	(8,067)	17
Other Expenses		(3,861)	(2,473)	56	(11,703)	(7,546)	55
Finance Costs	5	(772)	(860)	(10)	(3,021)	(4,058)	(26)
Other (Losses) Gains - Net	4	(220)	414	NM	3,689	253	NM
Share of (Loss) Profit from Equity-Accounted Associates		(357)	39	NM	(465)	159	NM
<b>Profit Before Tax from Continuing Operations</b>		<b>6,882</b>	<b>7,390</b>	(7)	<b>46,654</b>	<b>22,371</b>	109
Income Tax Expense	6	(2,939)	(1,481)	98	(7,296)	(2,533)	188
<b>Profit From Continuing Operations, Net of Tax</b>		<b>3,943</b>	<b>5,909</b>	(33)	<b>39,358</b>	<b>19,838</b>	98
<b>Other Comprehensive Income:</b>							
Exchange Differences on Translating Foreign Operations, Net of Tax		212	147	44	960	1,048	(8)
<b>Other Comprehensive Income for the Period/Year, Net of Tax</b>		<b>212</b>	<b>147</b>	44	<b>960</b>	<b>1,048</b>	(8)
<b>Total Comprehensive Income for the Period/Year</b>		<b>4,155</b>	<b>6,056</b>	(31)	<b>40,318</b>	<b>20,886</b>	93
<b>Profit Attributable to:</b>							
Owners of the Parent, Net of Tax		3,165	5,928	(47)	30,471	19,701	55
Non-Controlling Interests, Net of Tax		778	(19)	NM	8,887	137	NM
<b>Profit, Net of Tax</b>		<b>3,943</b>	<b>5,909</b>	(33)	<b>39,358</b>	<b>19,838</b>	98
<b>Total Comprehensive Income Attributable to:</b>							
Owners of the Parent		3,380	6,061	(44)	31,443	20,660	52
Non-Controlling Interests		775	(5)	NM	8,875	226	NM
<b>Total Comprehensive Income</b>		<b>4,155</b>	<b>6,056</b>	(31)	<b>40,318</b>	<b>20,886</b>	93
<b>EBITDA</b>		<b>10,387</b>	<b>11,805</b>	(12)	<b>63,254</b>	<b>37,676</b>	68

NM: Not Meaningful



**Q & M Dental Group (Singapore) Limited**  
(Incorporated in the Republic of Singapore)  
(Company Registration No: 200800507R)

	Note	Group				
		Fourth Quarter		Year-To-Date		
		Q4 2021 \$'000	Q4 2020 \$'000		31/12/2021 \$'000	31/12/2020 \$'000
<b>Earnings Per Share</b> Based on the Weighted Average Number of Ordinary <sup>(a)</sup> Shares on Issue – Cents Fully Diluted Basis – Cents						
		0.34	0.63		3.23	2.09
		0.34	0.63		3.23	2.09

- (a) The basic EPS for the period ended 31 December 2021 and 31 December 2020 are based on the profit attributable to equity holders of parent, net of tax and weighted average number of ordinary shares of 943,738,292 and 944,384,654 shares respectively.



**1(b) Condensed Interim Statements of Financial Position**

	Note	Group		Company	
		As at		As at	
		31/12/2021	31/12/2020 (Restated)	31/12/2021	31/12/2020
		\$'000	\$'000	\$'000	\$'000
<b>ASSETS</b>					
<b>Non-Current Assets</b>					
Property, Plant and Equipment	8	32,604	28,884	918	930
Right-Of-Use Assets		51,716	49,521	1,295	633
Investment in Subsidiaries		-	-	61,943	65,273
Investment in Associates	9	27,044	43,743	33,383	32,964
Goodwill	10	56,597	53,791	-	-
Other Intangible Assets	11	3,580	2,814	-	-
Other Receivables		2,401	1,199	2,068	822
Other Assets		7,080	8,568	3,777	3,939
<b>Total Non-Current Assets</b>		<b>181,022</b>	<b>188,520</b>	<b>103,384</b>	<b>104,561</b>
<b>Current Assets</b>					
Inventories		15,892	16,092	-	-
Trade and Other Receivables		27,823	18,190	89,739	95,688
Other Assets		3,833	3,226	1,494	1,703
Cash and Cash Equivalents		47,611	48,772	2,661	5,123
<b>Total Current Assets</b>		<b>95,159</b>	<b>86,280</b>	<b>93,894</b>	<b>102,514</b>
<b>Total Assets</b>		<b>276,181</b>	<b>274,800</b>	<b>197,278</b>	<b>207,075</b>
<b>EQUITY AND LIABILITIES</b>					
<b>Equity Attributable to Owners of the Parent</b>					
Share Capital	12	86,758	86,758	86,758	86,758
Treasury Shares	12	(13,950)	(10,897)	(13,950)	(10,897)
Retained Earnings		27,252	47,156	11,961	28,523
Other Reserves, Total		(2,211)	(1,937)	-	-
<b>Equity Attributable to Owners of the Parent, Total</b>		<b>97,849</b>	<b>121,080</b>	<b>84,769</b>	<b>104,384</b>
Non-Controlling Interests		5,397	3,615	-	-
<b>Total Equity</b>		<b>103,246</b>	<b>124,695</b>	<b>84,769</b>	<b>104,384</b>
<b>Non-Current Liabilities</b>					
Provisions		776	850	-	-
Deferred Tax Liabilities		2,393	1,160	-	-
Lease Liabilities Arising from Right-Of-Use Assets		44,296	42,143	1,131	509
Other Financial Liabilities	13	80,176	75,456	78,408	71,788
<b>Total Non-Current Liabilities</b>		<b>127,641</b>	<b>119,609</b>	<b>79,539</b>	<b>72,297</b>
<b>Current Liabilities</b>					
Income Tax Payable		5,595	2,633	-	-
Trade and Other Payables		26,239	16,791	29,536	29,014
Lease Liabilities Arising from Right-Of-Use Assets		9,908	9,131	189	134
Other Financial Liabilities	13	3,552	1,941	3,245	1,246
<b>Total Current Liabilities</b>		<b>45,294</b>	<b>30,496</b>	<b>32,970</b>	<b>30,394</b>
<b>Total Liabilities</b>		<b>172,935</b>	<b>150,105</b>	<b>112,509</b>	<b>102,691</b>
<b>Total Equity and Liabilities</b>		<b>276,181</b>	<b>274,800</b>	<b>197,278</b>	<b>207,075</b>



**1(c) Condensed Interim Consolidated Statement of Cash Flows**

	Group			
	Fourth Quarter		Year-To-Date	
	Q4 2021	Q4 2020	31/12/2021	31/12/2020
	\$'000	\$'000	\$'000	\$'000
<b>Cash Flows From (Used in) Operating Activities</b>				
Profit Before Tax	6,882	7,390	46,654	22,371
Adjustments for:				
Interest Income	(6)	(27)	(11)	(278)
Interest Expense	772	860	3,021	4,058
Loss (Gain) on Disposal of Plant and Equipment	1	-	(9)	43
Plant and Equipment Written Off	110	73	216	108
Share of Loss (Profit) from Equity – Associated Associates	357	(39)	465	(159)
Gain on Disposal of interest in Associates	-	-	(4,373)	-
Impairment of Plant and Equipment	-	-	(17)	6
Depreciation of Property, Plant and Equipment and Amortisation	1,109	893	4,134	3,458
Depreciation of Right-Of-Use Assets	1,630	2,689	9,456	8,067
Foreign Currency Translation Reserve	(85)	(135)	52	7
Provision	-	25	(74)	253
<b>Operating Cash Flows Before Changes in Working Capital</b>	<b>10,770</b>	<b>11,729</b>	<b>59,514</b>	<b>37,934</b>
Inventories	1,644	(21)	199	(9,057)
Trade and Other Receivables	7,768	1,331	(9,848)	(1,920)
Other non-financial assets	283	1,183	(170)	92
Trade and Other Payables	(1,378)	(691)	4,220	(2,136)
Net Cash Flows From Operating Activities Before Interest and Tax	<b>19,087</b>	<b>13,531</b>	<b>53,915</b>	<b>24,913</b>
Income Taxes Refunded (Paid)	191	(215)	(3,112)	(1,162)
<b>Net Cash Flows From Operating Activities</b>	<b>19,278</b>	<b>13,316</b>	<b>50,803</b>	<b>23,751</b>
<b>Cash Flows (Used in) From Investing Activities</b>				
Purchase of Plant and Equipment	(2,888)	(2,120)	(7,874)	(6,390)
Purchase of Intangible Assets	28	(199)	(1,061)	(873)
Disposal of Plant and Equipment	149	81	293	268
Other non-financial assets	145	555	(805)	928
Trade and Other Receivables	-	1,109	375	608
Increase in Investment in Associate	-	(316)	(420)	(496)
Proceeds from Partial Disposal of Associate	-	-	17,002	47,515
Dividend Received from Associate	-	-	-	1,282
Acquisition of subsidiary	(2,850)	(400)	(2,850)	(400)
Other Receivables, Non-Current	(1,285)	(987)	(1,202)	(967)
Interest Received	6	27	11	278
<b>Net Cash Flows (Used in) From Investing Activities</b>	<b>(6,695)</b>	<b>(2,250)</b>	<b>3,469</b>	<b>41,753</b>
<b>Cash Flows Used in Financing Activities</b>				
Lease Liabilities – Principal Portion Paid	(1,283)	(2,235)	(8,787)	(6,985)
Lease Liabilities – Interest Paid	(422)	(443)	(1,599)	(1,837)
Finance Lease Repayment	(5)	(3)	(20)	(10)
Proceeds from Finance Lease	-	-	75	-
Repayment of Bank Loans	(96)	(8,023)	(1,465)	(9,374)
Share Buy Back	(3,053)	-	(3,053)	(1,529)
Proceeds from Term Loan	-	-	10,000	-
Bill Payables	78	562	(402)	193
Interest Paid	(350)	(417)	(1,422)	(2,221)
Dividends Paid to Equity Owners	(9,395)	-	(48,760)	(22,222)
<b>Net Cash Flows Used In Financing Activities</b>	<b>(14,526)</b>	<b>(10,559)</b>	<b>(55,433)</b>	<b>(43,985)</b>



**Q & M Dental Group (Singapore) Limited**  
(Incorporated in the Republic of Singapore)  
(Company Registration No: 200800507R)

	Group			
	Fourth Quarter		Year-To-Date	
	Q4 2021	Q4 2020	31/12/2021	31/12/2020
	\$'000	\$'000	\$'000	\$'000
<b>Net (Decrease) Increase in Cash and Cash Equivalents</b>	(1,943)	507	(1,161)	21,519
Cash and Cash Equivalents, Statement of Cash Flows, Beginning Balance of the Period/Year	49,554	48,265	48,772	27,253
<b>Cash and Cash Equivalents, Statement of Cash Flows, Ending Balance of the Period/Year</b>	<b>47,611</b>	<b>48,772</b>	<b>47,611</b>	<b>48,772</b>
<b>Cash and Cash Equivalents at End of Period/Year includes the following:</b>				
Cash and Bank Balances	47,611	48,772	47,611	48,772
<b>Cash and Cash Equivalents at End of Period/Year</b>	<b>47,611</b>	<b>48,772</b>	<b>47,611</b>	<b>48,772</b>



**1(d)(i) Condensed Interim Statements of Changes in Equity**

	<u>Total Equity</u>	<u>Attributable to Parent Sub-total</u>	<u>Share Capital</u>	<u>Retained Earnings</u>	<u>Treasury Shares</u>	<u>Other Reserves</u>	<u>Non-Controlling Interest</u>
	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
<b>Group - Current Year</b>							
Opening Balance at 1 January 2021	124,695	121,080	86,758	47,156	(10,897)	(1,937)	3,615
<b>Movements in Equity:</b>							
Total Comprehensive Income for the Year	40,318	31,443	-	30,471	-	972	8,875
Share Buy Back	(3,053)	(3,053)	-	-	(3,053)	-	-
Decrease in Non-Controlling Interest without a change in Control	(5,054)	(1,246)	-	-	-	(1,246)	(3,808)
Dividends paid to Non-Controlling Interest	(4,900)	(1,615)	-	(1,615)	-	-	(3,285)
Dividends Paid (Note 7)	(48,760)	(48,760)	-	(48,760)	-	-	-
Closing Balance at 31 December 2021	103,246	97,849	86,758	27,252	(13,950)	(2,211)	5,397
<b>Group - Previous Year</b>							
Opening Balance at 1 January 2020	123,130	121,973	86,758	49,677	(11,558)	(2,904)	1,157
<b>Movements in Equity:</b>							
Total Comprehensive Income for the Year	20,886	20,660	-	19,701	-	959	226
Share Buy Back	(1,529)	(1,529)	-	-	(1,529)	-	-
Issue of Share Capital	2,190	2,190	-	-	2,190	-	-
Dividends Paid (Note 7)	(22,222)	(22,222)	-	(22,222)	-	-	-
Decrease in Non-Controlling Interest without a change in Control	-	8	-	-	-	8	(8)
Contribution by Non-Controlling Interest (Restated)	2,240	-	-	-	-	-	2,240
Closing Balance at 31 December 2020	124,695	121,080	86,758	47,156	(10,897)	(1,937)	3,615



**1(d)(ii) Condensed Interim Statements of Changes in Equity**

	<u>Total Equity</u>	<u>Share Capital</u>	<u>Treasury Shares</u>	<u>Other Reserve</u>	<u>Retained Earnings</u>
	\$'000	\$'000	\$'000	\$'000	\$'000
<b>Company - Current Year</b>					
Opening Balance at 1 January 2021	104,384	86,758	(10,897)	-	28,523
<b>Movements in Equity:</b>					
Total Comprehensive Income for the Year	32,198	-	-	-	32,198
Share Buy Back	(3,053)	-	(3,053)	-	-
Dividends Paid (Note 7)	(48,760)	-	-	-	(48,760)
Closing Balance at 31 December 2021	84,769	86,758	(13,950)	-	11,961
<b>Company - Previous Year</b>					
Opening Balance at 1 January 2020	106,921	86,758	(11,558)	-	31,721
<b>Movements in Equity:</b>					
Total Comprehensive Income for the Year	19,024	-	-	-	19,024
Share Buy Back	(1,529)	-	(1,529)	-	-
Issue of Share Capital	2,190	-	2,190	-	-
Dividends Paid (Note 7)	(22,222)	-	-	-	(22,222)
Closing Balance at 31 December 2020	104,384	86,758	(10,897)	-	28,523



**Q & M Dental Group (Singapore) Limited**  
(Incorporated in the Republic of Singapore)  
(Company Registration No: 200800507R)

**1(e) Notes to the Condensed Interim Financial Statements**  
**31 December 2021**

**1. General**

The Company is incorporated in Singapore with limited liability. The financial statements are presented in Singapore dollars and they cover the Company (referred to as “parent”) and the subsidiaries. The registered office is: 2 Clementi Loop, #04-01 Logis Hub @ Clementi, Singapore 129809. The Company is situated in Singapore.

The board of directors approved and authorised these condensed financial statements for issue on the date of this announcement. The directors have the power to amend and reissue the financial statements.

The principal activities of the Company are the provision of management and consultancy services and investment holding. It is listed on the Singapore Exchange Securities Trading Limited, (“SGX-ST”).

The principal activities of the group are disclosed in Note 2 on segment information.

The financial information contained in this announcement has neither been audited nor review by the auditors.

The latest audited annual financial statements were not subject to an adverse opinion, qualified opinion or disclaimer of opinion.

**Basis of presentation**

These condensed consolidated interim financial statements have been prepared in accordance with the Singapore Financial Reporting Standards (International) (“SFRS (I) s”) 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. They are also in compliance with the International Financial Reporting Standards (IFRSs) issued by the International Accounting Standards Board (IASB) and the provisions of the SGX Mainboard Listing Rules.

The accounting policies and methods of computation applied in these condensed consolidated interim financial statements are consistent with those of the latest audited annual financial statements for the reporting year ended 31 December 2020. However, the typical notes and information included in the latest audited annual financial statements are not included in these interim financial statements except for the selected explanatory notes included to explain events and transactions that are significant to an understanding of the changes in the performance and financial position of the group since the latest audited annual financial statements.

**New and amended standards adopted by the Group**

A number of amendments to Standards have become applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.



### **Critical judgements, assumptions and estimation uncertainties**

These estimates and assumptions are periodically monitored to ensure they incorporate all relevant information available at the date when financial statements are prepared. However, this does not prevent actual figures differing from estimates. The nature and the carrying amount of such significant assets and liabilities are disclosed with further details in the relevant Notes to these condensed consolidated interim financial statements.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 December 2020.

## **2. Financial information by operating segments**

### **2A. Information about reportable segment profit or loss, assets and liabilities**

The following summary describes the operations in each of the Group's operating segments:

- (i) Primary healthcare comprising dentistry, family medicine, aesthetic services and others.
- (ii) Medical laboratory and dental equipment and supplies comprising sale and distribution of Covid-19 test kits and provision of laboratory testing and distribution of dental supplies and equipment.



**Q & M Dental Group (Singapore) Limited**  
(Incorporated in the Republic of Singapore)  
(Company Registration No: 200800507R)

**2B(i). Profit or loss for the 3 months ended 31 December from continuing operations and reconciliations**

	<u>Primary Healthcare</u>		<u>Medical Laboratory and Dental Equipment &amp; Supplies</u>		<u>Unallocated – Investment in Associates</u>		<u>Consolidated</u>	
	2021 \$'000	2020 \$'000	2021 \$'000	2020 \$'000	2021 \$'000	2020 \$'000	2021 \$'000	2020 \$'000
Revenue by segment	43,935	40,867	11,590	4,124	-	-	55,525	44,991
Inter-segment sales	(340)	(66)	(1,891)	(1,103)	-	-	(2,231)	(1,169)
<b>Total revenue</b>	<b>43,595</b>	<b>40,801</b>	<b>9,699</b>	<b>3,021</b>	<b>-</b>	<b>-</b>	<b>53,294</b>	<b>43,822</b>
Segment results	8,230	11,012	2,520	115	(357)	39	10,393	11,166
Job support scheme and rental rebate	-	560	-	106	-	-	-	666
Segment results	8,230	11,572	2,520	221	(357)	39	10,393	11,832
Finance costs							(772)	(860)
Depreciation of plant and equipment							(962)	(830)
Depreciation right-of-use assets							(1,630)	(2,689)
Amortisation of intangible assets							(147)	(63)
Profit before income tax							6,882	7,390
Income tax expense							(2,939)	(1,481)
<b>Profit, net of tax</b>							<b>3,943</b>	<b>5,909</b>
<b>Expenditure for non-current assets</b>								
Property, plant and equipment	(2,449)	(1,549)	(439)	(571)	-	-	(2,888)	(2,120)
<b>Other material non-cash items</b>								
Depreciation of plant and equipment	(796)	(753)	(166)	(77)	-	-	(962)	(830)
Depreciation right-of-use assets	(1,536)	(2,643)	(94)	(46)	-	-	(1,630)	(2,689)
Amortisation of intangible assets	(73)	(63)	(74)	-	-	-	(147)	(63)
Finance costs	(753)	(845)	(19)	(15)	-	-	(772)	(860)
Allowance on inventories	-	-	(94)	-	-	-	(94)	-
Allowance on trade receivables	-	180	(20)	-	-	-	(20)	180



**Q & M Dental Group (Singapore) Limited**  
(Incorporated in the Republic of Singapore)  
(Company Registration No: 200800507R)

**2B(ii). Profit or loss for the 12 months ended 31 December from continuing operations and reconciliations**

	<u>Primary Healthcare</u>		<u>Medical Laboratory and Dental Equipment &amp; Supplies</u>		<u>Unallocated – Investment in Associates</u>		<u>Consolidated</u>	
	2021 \$'000	2020 \$'000	2021 \$'000	2020 \$'000	2021 \$'000	2020 \$'000	2021 \$'000	2020 \$'000
Revenue by segment	160,749	126,642	51,340	14,827	-	-	212,089	141,469
Inter-segment sales	(538)	(264)	(5,952)	(3,585)	-	-	(6,490)	(3,849)
<b>Total revenue</b>	<b>160,211</b>	<b>126,378</b>	<b>45,388</b>	<b>11,242</b>	<b>-</b>	<b>-</b>	<b>205,599</b>	<b>137,620</b>
Segment results	36,984	33,433	22,373	1,092	3,908	159	63,265	34,684
Job support scheme	-	3,096	-	174	-	-	-	3,270
Segment results	36,984	36,529	22,373	1,266	3,908	159	63,265	37,954
Finance costs							(3,021)	(4,058)
Depreciation of plant and equipment							(3,741)	(3,204)
Depreciation right-of-use assets							(9,456)	(8,067)
Amortisation of intangible assets							(393)	(254)
Profit before income tax							46,654	22,371
Income tax expense							(7,296)	(2,533)
<b>Profit, net of tax</b>							<b>39,358</b>	<b>19,838</b>
<b>Expenditure for non-current assets</b>								
Property, plant and equipment	(5,874)	(3,605)	(2,000)	(2,785)	-	-	(7,874)	(6,390)
<b>Other material non-cash items</b>								
Depreciation of plant and equipment	(3,232)	(3,008)	(509)	(196)	-	-	(3,741)	(3,204)
Depreciation right-of-use assets	(9,248)	(7,996)	(208)	(71)	-	-	(9,456)	(8,067)
Amortisation of intangible assets	(263)	(254)	(130)	-	-	-	(393)	(254)
Finance costs	(2,972)	(4,042)	(49)	(16)	-	-	(3,021)	(4,058)
Gain on deem disposal of associate	-	-	-	-	4,373	-	4,373	-
Allowance on inventories	-	-	(377)	-	-	-	(377)	-
Allowance on trade receivables	-	180	(75)	-	-	-	(75)	180
Allowance on plant and equipment	17	(6)	-	-	-	-	17	(6)



**2C. Assets and reconciliation**

	As at	
	31 Dec 2021 \$'000	31 Dec 2020 \$'000
<u>Segment assets</u>		
Primary healthcare	200,241	204,774
Medical laboratory and dental equipment and supplies	48,897	26,283
Unallocated – investment in associates	27,043	43,743
Total	<u>276,181</u>	<u>274,800</u>

**2D. Liabilities and reconciliation**

	As at	
	31 Dec 2021 \$'000	31 Dec 2020 \$'000
<u>Segment liabilities</u>		
Primary healthcare	157,813	146,210
Medical laboratory and dental equipment and supplies	15,122	3,895
Total	<u>172,935</u>	<u>150,105</u>

**2E. Geographical information**

The Group operations are primarily in Singapore, Malaysia and China.

	3 months ended 31 Dec		12 months ended 31 Dec	
	2021 \$'000	2020 \$'000	2021 \$'000	2020 \$'000
<u>Revenue</u>				
Singapore	49,976	40,288	194,140	126,596
Malaysia	2,993	3,198	10,252	9,752
China	325	336	1,207	1,272
Total	<u>53,294</u>	<u>43,822</u>	<u>205,599</u>	<u>137,620</u>

	As at	
	31 Dec 2021 \$'000	31 Dec 2020 \$'000
<u>Non-current assets</u>		
Singapore	149,153	138,116
Malaysia	4,462	4,227
China	27,407	46,177
Total	<u>181,022</u>	<u>188,520</u>

Revenues are attributed to countries on the basis of the customer's location, irrespective of the origin of the goods and services. The non-current assets are analysed by the geographical area in which the assets are located.



### 3. Revenue

	3 months ended 31 Dec		12 months ended 31 Dec	
	<u>2021</u>	<u>2020</u>	<u>2021</u>	<u>2020</u>
	\$'000	\$'000	\$'000	\$'000
Dental, medical and laboratory testing services	49,579	41,176	193,083	125,620
Sales of goods	2,456	2,349	8,228	8,763
Profit guarantee income	1,178	(3)	3,179	2,169
Rental income	105	122	540	471
Other income	(24)	178	569	597
Total revenue	<u>53,294</u>	<u>43,822</u>	<u>205,599</u>	<u>137,620</u>

### 4. Other gains and (other losses)

	3 months ended 31 Dec		12 months ended 31 Dec	
	<u>2021</u>	<u>2020</u>	<u>2021</u>	<u>2020</u>
	\$'000	\$'000	\$'000	\$'000
(Loss) gain on disposal of plant and equipment	(1)	-	9	(43)
Plant and equipment written off	(110)	(73)	(216)	(108)
Foreign exchange translation gain (loss)	5	307	(42)	230
Gain on deem disposal of associate	-	-	4,373	-
Impairment allowance on other receivables – (loss) / reversal	(20)	180	(75)	180
Impairment allowance on plant and equipment – reversal / (loss)	-	-	17	(6)
Impairment allowance on inventories	(94)	-	(377)	-
Net	<u>(220)</u>	<u>414</u>	<u>3,689</u>	<u>253</u>

### 5. Finance costs

	3 months ended 31 Dec		12 months ended 31 Dec	
	<u>2021</u>	<u>2020</u>	<u>2021</u>	<u>2020</u>
	\$'000	\$'000	\$'000	\$'000
Interest on borrowings	350	417	1,422	2,221
Interest on lease liabilities	422	443	1,599	1,837
Net	<u>772</u>	<u>860</u>	<u>3,021</u>	<u>4,058</u>



## 6. Income tax expense

### Components of tax expense recognised in profit or loss include:

	3 months ended 31 Dec		12 months ended 31 Dec	
	<u>2021</u>	<u>2020</u>	<u>2021</u>	<u>2020</u>
	\$'000	\$'000	\$'000	\$'000
<u>Current tax expense:</u>				
Current tax expense	1,357	1,564	5,906	2,510
Under adjustments in respect of prior periods	102	157	167	262
Subtotal	<u>1,459</u>	<u>1,721</u>	<u>6,073</u>	<u>2,772</u>
<u>Deferred tax expense (income):</u>				
Deferred tax expense (income)	941	(542)	909	(574)
Under adjustments in respect of prior periods	539	302	314	335
Subtotal	<u>1,480</u>	<u>(240)</u>	<u>1,223</u>	<u>(239)</u>
Total income tax expense	<u>2,939</u>	<u>1,481</u>	<u>7,296</u>	<u>2,533</u>

## 7. Dividends on equity shares

	Group	
	31 Dec <u>2021</u> \$'000	31 Dec <u>2020</u> \$'000
Interim tax exempt dividend paid of \$0.0242 with respect of FY2019	-	19,053
Interim tax exempt dividend paid of \$0.004 with respect of 1H2020	-	3,169
Second interim tax exempt dividend paid of \$0.025 with respect of FY2020	19,683	-
Final tax exempt dividend paid of \$0.005 with respect of FY2020	3,936	-
First tax exempt dividend paid of \$0.010 with respect of 1Q2021	7,873	-
Second interim tax exempt dividend paid of \$0.01 with respect of 2Q2021	7,873	-
Third interim tax exempt dividend paid of \$0.01 with respect of 3Q2021	9,395	-
	<u>48,760</u>	<u>22,222</u>

## 8. Property, plant and equipment

During the twelve months ended 31 December 2021, the Group acquired assets amounting to \$7,874,000 (31 December 2020: \$6,390,000) and disposed of assets amounting to \$216,000 (31 December 2020: \$108,000).



## 9. Investment in associates

	Group As at	
	31 Dec <u>2021</u> \$'000	31 Dec <u>2020</u> \$'000
Movements in carrying value:		
Balance at beginning of the year	43,743	42,026
Additions	420	496
Disposals	(12,623)	-
Dilution	(5,054)	-
Foreign currency translation adjustment	1,023	1,062
Share of (loss) profit for the year	(465)	159
	<u>27,044</u>	<u>43,743</u>

In April 2021, the Group completed the disposal of the balance 12.3% registered capital of Aidite Qinhuangdao (“Aidite”).

Following the acquisition of 49% shareholding of Acumen Diagnostics Pte. Ltd. on 1 November 2021 by Aoxin Q&M Dental Group Limited (“Aoxin Q&M”), the Group’s shareholding of Aoxin Q&M was diluted from 43.9% to 32.95%.

The closing share price of Aoxin Q & M as at 31 December 2021 was \$0.24 per share. The Company’s shareholding in Aoxin Q & M has a market valuation of \$40.24 million as at 31 December 2021.

## 10. Goodwill

Goodwill that have an indefinite useful life are tested for impairment annually, or more frequently if events or changes in circumstances indicated that it might be impaired. No impairment indicators were identified as at 31 December 2021 based on the CGU’s business performance.

The goodwill increased by \$2.8 million due to the acquisition of Acumen Research Laboratories Pte. Ltd. by the Group’s 51% owned subsidiary, Acumen Diagnostics Pte. Ltd. on 1 November 2021.

Since the beginning of the reporting year, there were no changes in the circumstances and key assumptions.



## 11. Other intangible assets

	Development costs \$'000	Customer lists \$'000	Total \$'000
As at 31 December 2020:			
Cost	1,298	2,764	4,062
Accumulated amortisation and impairment	-	(1,248)	(1,248)
Carrying amounts	1,298	1,516	2,814
As at 31 December 2021:			
Cost	\$'000	\$'000	\$'000
As at 1 January 2021	1,298	2,764	4,062
Additions	1,160	-	1,160
As at 31 December 2021	2,458	2,764	5,222
Accumulated amortisation and impairment			
As at 1 January 2021	-	1,248	1,248
Amortisation	10	384	394
As at 31 December 2021	10	1,632	1,642
Carrying amounts at 31 December 2021	2,448	1,132	3,580

## 12. Share capital

	Number of shares issued '000	Share capital \$'000
Ordinary shares of no par value:		
Balance at 31 December 2020	804,887	86,758
Bonus issue <sup>(a)</sup>	160,978	-
Balance at 31 December 2021	965,865	86,758

<sup>(a)</sup> On 7 September 2021, 160,977,547 bonus shares had been allotted and issued.

The ordinary shares of no par value are fully paid, carry one vote each and have no right to fixed income.

	Number of treasury shares '000	Cost \$'000
Balance at 31 December 2020	17,578	10,897
Bonus issue <sup>(b)</sup>	3,516	-
Share buyback <sup>(c)</sup>	5,328	3,053
Balance at 31 December 2021	26,422	13,950

<sup>(b)</sup> On 7 September 2021, the Company received 3,515,834 bonus treasury shares.



## 12. Share capital (cont'd)

(c) In FY2021, the Company bought back 5,327,400 shares by way of market acquisition and all shares are held as treasury shares.

The Company has 26,422,407 treasury shares as at 31 December 2021 (31 December 2020: 17,579,173) and there is no subsidiary holdings as at 31 December 2021 (31 December 2020: Nil).

	As at	
	31 Dec <u>2021</u>	31 Dec <u>2020</u>
Total number of issued shares excluding treasury shares	<u>939,442,940</u>	<u>944,770,340</u>

There were no sales, transfer, disposals, cancellation and/or use of treasury shares as at end of current financial year reported on.

## 13. Other financial liabilities

	Group As at		Company As at	
	31 Dec <u>2021</u> \$'000	31 Dec <u>2020</u> \$'000	31 Dec <u>2021</u> \$'000	31 Dec <u>2020</u> \$'000
<u>Non-current:</u>				
Bank loans	80,097	73,563	78,408	71,788
Finance leases	79	36	-	-
Redeemable preference shares	-	1,857	-	-
Non-current, total	<u>80,176</u>	<u>75,456</u>	<u>78,408</u>	<u>71,788</u>
<u>Current:</u>				
Bank loans	3,371	1,371	3,245	1,246
Finance leases	21	8	-	-
Bills payable	160	562	-	-
Current, total	<u>3,552</u>	<u>1,941</u>	<u>3,245</u>	<u>1,246</u>
Total	<u>83,728</u>	<u>77,397</u>	<u>81,653</u>	<u>73,034</u>

### 13A. Bank loans

	Group As at		Company As at	
	31 Dec <u>2021</u> \$'000	31 Dec <u>2020</u> \$'000	31 Dec <u>2021</u> \$'000	31 Dec <u>2020</u> \$'000
Amount repayable within one year	3,371	1,371	3,245	1,246
Amount repayable after one year	<u>80,097</u>	<u>73,563</u>	<u>78,408</u>	<u>71,788</u>

Bank loans amounting to \$7.5 million (31 December 2020: \$7.9 million) are secured by legal mortgage of the Group's properties and covered by corporate guarantee from the Company.



**13. Other financial liabilities (cont'd)**

**13B. Finance leases**

	Group As at	
	31 Dec <u>2021</u> \$'000	31 Dec <u>2020</u> \$'000
Amount repayable within one year	21	8
Amount repayable after one year	<u>79</u>	<u>36</u>

The finance leases are secured on the plant and equipment under finance leases.

**13C. Bills payable**

	Group As at	
	31 Dec <u>2021</u> \$'000	31 Dec <u>2020</u> \$'000
Amount repayable within one year	<u>160</u>	<u>562</u>

The bills payable of the subsidiary are secured or covered by the following:

- (i) Facilities Agreement;
- (ii) Corporate guarantee by the Company;
- (iii) Jointly and severally guarantees by certain directors of the subsidiary;
- (iv) Negative pledge;
- (v) Fixed deposit; and
- (vi) Trade Financing General Agreement from the subsidiary.

The bill payables of the Group have maturity period of 90 days (2020: 90 days).

**13C. Redeemable preference shares**

	Group As at	
	31 Dec <u>2021</u> \$'000	31 Dec <u>2020</u> \$'000
Amount repayable after one year	<u>-</u>	<u>1,857</u>

On 8 April 2021, the Group completed the disposal of the balance 12.3% registered capital of Aidite Qinhuangdao.



#### 14. Categories of financial assets and liabilities

The following table categories the carrying amount of financial assets and liabilities recorded at the end of the reporting period:

	Group As at		Company As at	
	31 Dec 2021 \$'000	31 Dec 2020 \$'000	31 Dec 2021 \$'000	31 Dec 2020 \$'000
<u>Financial assets:</u>				
Financial assets at amortised cost	77,835	68,161	94,468	101,633
At end of the period	<u>77,835</u>	<u>68,161</u>	<u>94,468</u>	<u>101,633</u>
<u>Financial liabilities</u>				
Financial liabilities at amortised cost	164,171	145,462	112,509	102,691
At end of period	<u>164,171</u>	<u>145,462</u>	<u>112,509</u>	<u>102,691</u>

#### 15. Net asset value

	Group As at		Company As at	
	31 Dec 2021	31 Dec 2020	31 Dec 2021	31 Dec 2020
Net assets value per ordinary share (cents)	<u>10.4</u>	<u>12.8</u>	<u>9.0</u>	<u>11.0</u>

The net asset value per ordinary share of the Group and the Company as at 31 December 2021 has been calculated based on the total issued number of ordinary shares excluding treasury shares of 939,442,940 (2020: 944,770,340).

#### 16. Events after the end of the reporting period

On 17 January 2022, the Company announced that Acumen Diagnostics Pte. Ltd. ("AD"), its 51% owned subsidiary, is exploring a proposed listing of its securities on the NASDAQ stock exchange in New York, USA. AD has appointed UOB Kay Hian Private Limited to assist AD with the listing evaluation and all relevant preparatory work including the selection of professional advisers and underwriting banks in relation to the proposed NASDAQ listing and fund raising exercise.

There are no other known subsequent events which have led to adjustments to this set of condensed interim financial statements.



## 17. Reclassifications and restatement of comparative figures

Certain reclassifications and restatements were made in the balances in the financial statements for last year. The material changes in the balances included the following:

		After \$'000	Before \$'000	Difference \$'000
<u>31.12.2020 Statement of Financial Position:</u>				
Goodwill	10	53,791	53,144	647
Intangible assets	11	2,814	2,441	373
Trade and other payables		(16,791)	(16,541)	(250)
Non-controlling interests		<u>(3,615)</u>	<u>(2,845)</u>	<u>(770)</u>

Restatement has been made to recognise goodwill, intangible assets, trade and other payables and non-controlling interests for the reporting year ended 31 December 2020 following the finalisation of the purchase price allocation exercise in relation to the Group's acquisition in 2020 of Acumen Diagnostics Pte. Ltd. to restate the identified assets and liabilities at fair value.



## **Other Information Required by Listing Rule 7.2**

**1. Whether the figures have been audited or reviewed and in accordance with auditing standards or practice.**

The condensed interim consolidated financial statement and notes for the fourth quarter ended 31 December 2021 have not been reviewed / audited by the Company's auditor.

**2. A review of the performance of the Group, to the extent necessary for a reasonable understanding of the Group's business. It must include a discussion of the following:**

- a) any significant factors that affected the turnover, costs, and earnings of the Group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and
- b) any material factors that affected the cash flow, working capital, assets or liabilities of the Group during the current financial period reported on.

### **Statement of Comprehensive Income**

#### **Revenue**

As at 31 December 2021, the Group has 97 dental outlets, 5 medical outlets and 1 dental college in operations in Singapore, compared to 83 dental outlets, 5 medical outlets and 1 dental college as at 31 December 2020. The Company opened 15 new clinics and consolidated 1 clinic in Singapore in 2021.

As at 31 December 2021, the Group has 38 dental outlets in Malaysia and 1 dental outlet in People's Republic of China ("PRC") compared to 34 dental outlets in Malaysia and 1 dental outlet in PRC as at 31 December 2020. The Company opened 4 new clinics in Malaysia in 2021.

As at 31 December 2021 and 31 December 2020, the Group has 1 dental equipment & supplies distribution company and a Covid-19 medical laboratory company in Singapore and 1 dental equipment & supplies distribution company in Malaysia.

Revenue contribution from dental and medical clinics increased by 7% from \$40.8 million for the three months ended 31 December 2020 ("4Q20") to \$43.6 million for the three months ended 31 December 2021 ("4Q21"). The increase of \$2.8 million was mainly due to higher revenue from existing and new dental clinics in Singapore.

Revenue contribution from medical laboratory and dental equipment & supplies increased by 221% from \$3.0 million in 4Q20 to \$9.7 million in 4Q21. The increase was mainly due to revenue from the Group's Covid-19 medical laboratory business. The medical laboratory license from MOH was obtained in September 2020.



Total revenue increased by 22% from \$43.8 million in 4Q20 to \$53.3 million 4Q21. The increase was mainly due to the revenue from the Group's Covid-19 medical laboratory business.

Total revenue increased by 49% from \$137.6 million for the 12 months ended 31 December 2020 ("FY20") to \$205.6 million for the 12 months ended 31 December 2021 ("FY21") for the same reasons given above.

#### **Other Gain – Net**

Other gain was \$3.7 million in FY21 as compared to \$0.3 million in FY20 mainly due to profit on disposal of Aidite in 1Q21.

#### **Other Items of Expense**

##### Consumables and Supplies Used in Dental & Medical Clinics

Consumables and supplies used decreased by 2% from \$3.7 million in 4Q20 to \$3.6 million in 4Q21.

As a percentage of revenue from the dental and medical outlets, consumables and supplies used in the dental and medical outlets in 4Q21 was 8.3% compared to 9.1% in 4Q20.

Comparing FY21 with FY20, consumables and supplies used in dental and medical clinics increased by 32% or \$3.4 million which was due to the increase in revenue as well as inflationary pressure leading to higher prices for consumables and supplies.

##### Cost of Sales from Medical Laboratory and Dental Equipment & Supplies

The cost of sales from medical laboratory and dental equipment & supplies increased by 202% from \$1.5 million in 4Q20 to \$4.7 million in 4Q21. The increase was mainly due to the increase in revenue of the Covid-19 medical laboratory business.

As a percentage of revenue from medical laboratory, cost of sales used in medical laboratory in 4Q21 was 48.0% compared to 51.0% in 4Q20.

Comparing FY21 with FY20, cost of sales from medical laboratory increased by 173% or \$10.6 million for the same reason given above.

##### Employee Benefits Expense

Employee benefits expense, which include professional fees paid to dentists, increased by 22% from \$24.8 million in 4Q20 to \$30.2 million in 4Q21. The increase of \$5.4 million was mainly due to increase in revenue from existing and new dental outlets in Singapore in 4Q21, the increase in revenue from the Covid-19 medical laboratory, provision of additional employee benefits in 4Q21.

As a percentage of revenue, employee benefits expense in 4Q21 was 56.7% compared to 56.5% in 4Q20.



Comparing FY21 with FY20, employee benefits expense increased by 36% or \$27.1 million. The increase in employee benefits expense for FY21 was due to increase in revenue from dental outlets and Covid-19 medical laboratory as well as provision of additional employee benefits off set by \$3.3 million Job Support Scheme received in FY20.

#### Depreciation and Amortisation Expense

Depreciation and amortisation expense increased by 24% from \$0.9 million in 4Q20 to \$1.1 million in 4Q21. The increase of \$0.2 million was mainly to higher depreciation and amortisation expense from the Covid-19 medical laboratory in Singapore for 4Q21.

As a percentage of revenue, depreciation and amortisation expense in 4Q21 was 2.1% compared to 2.0% in 4Q20.

Comparing FY21 with FY20, depreciation and amortisation expense increased by 20% or \$0.7 million for the same reason given above.

#### Depreciation of Right-Of-Use (“ROU”) Assets

Excluding the effect of rental rebate, depreciation of ROU assets increased by 2% from \$2.9 million in 4Q20 to \$3.0 million in 4Q21.

As a percentage of revenue, depreciation of ROU assets in 4Q21 was 5.0% compared to 6.7% in 4Q20.

Comparing FY21 with FY20, depreciation of ROU assets, excluding the effect of rental rebate, increased by 2% or \$0.2 million.

#### Other Expenses

Other expenses increased by 56% from \$2.5 million in 4Q20 to \$3.9 million in 4Q21. The increase of \$1.4 million was mainly due to higher revenue in 4Q21 which resulted in higher incidental expenses like credit card charges, legal and professional fees and increase in marketing expenses as well as increase in expenses incurred by the Covid-19 medical laboratory.

As a percentage of revenue, other expenses in 4Q21 was 7.2% compared to 5.6% in 4Q20.

Comparing FY21 with FY20, other expenses increased by 55% or \$4.2 million for the same reasons given above.

#### Finance Costs

Finance costs decreased by 10% from \$0.9 million in 4Q20 to \$0.8 million in 4Q21. The decrease was mainly due to lower interest expense in 4Q21 as a result of lower interest rate.

As a percentage of revenue, finance costs in 4Q21 was 1.4% compared to 2.0% in 4Q20.

Comparing FY21 with FY20, finance costs decreased by 26% or \$1.0 million for the same reason give above.



**Share of Loss from Equity-Accounted Associate**

Share of loss of \$0.4 million in 4Q21 was due to the 32.9% equity-accounted associate, Aoxin Q & M. Share of profit in 4Q20 mainly due to the share of profit from Aidite which was disposed by the Group in 1Q21.

**Profit Before Tax and Net Profit**

For the reasons given above, the Group's profit before tax decreased by 7% from \$7.4 million in 4Q20 to \$6.9 million in 4Q21.

Income tax expense increased by 98% from \$1.5 million in 4Q20 to \$2.9 million in 4Q21.

After deducting provision for income tax expense of \$2.9 million, the Group's net profit decreased by 33% from \$5.9 million in 4Q20 to \$3.9 million in 4Q21.

For FY21 the Group's net profit after tax increased by 98% to \$39.4 million compared to \$19.8 million for FY20.

Profit after tax attributable to owners of the parent increased by 55% from \$19.7 million for FY20 to \$30.5 million for FY21.

**Statement of Financial Position**

As at 31 December 2021, the Group has cash and cash equivalents of \$47.6 million while bank borrowings plus finance leases amounted to \$83.7 million. As at 31 December 2020, the Group has cash and cash equivalents of \$48.8 million while bank borrowings plus finance leases amounting to \$77.4 million.

**Current Assets**

Cash and cash equivalents as at 31 December 2021 decreased to \$47.6 million from \$48.8 million as at 31 December 2020. The decrease of \$0.8 million was mainly due to dividend payment of \$48.8 million to shareholders offset by proceeds from new term loan of \$10.0 million, \$17.0 million of net proceeds from disposal of the remaining 12.3% of equity-accounted associate, Aidite (Qinhuangdao) Technology Co and net cash generated from operations of \$50.8 million (FY20: \$23.8 million).

Trade and other receivables as at 31 December 2021 increased to \$27.8 million from \$18.2 million as at 31 December 2020. The increase of \$9.6 million was mainly due to increase in trade receivables from the Covid-19 medical laboratory testing business and profit guarantee receivables from vendors of Aoxin Q & M Dental Group Limited, an equity-accounted associate of the Company.

Other assets as at 31 December 2021 increased to \$3.8 million from \$3.2 million as at 31 December 2020. The increase of \$0.6 million was mainly due to an increase in sign on bonus for dentists.



### **Non-Current Assets**

The net book value of property, plant and equipment as at 31 December 2021 increased to \$32.6 million from \$28.9 million as at 31 December 2020. The increase of \$3.7 million was mainly due to the purchase of equipment for the Covid-19 medical laboratory and opening of new dental clinics in Singapore offset by depreciation of plant and equipment.

The net book value of ROU assets as at 31 December 2021 increased to \$51.7 million from \$49.5 million as at 31 December 2020. The increase was due to the opening of new dental clinics in Singapore offset by depreciation of the ROU assets.

Investment in associates as at 31 December 2021 decreased to \$27.0 million from \$43.7 million as at 31 December 2020. The decrease of \$16.7 million was mainly due to the disposal of the balance 12.3% of equity-accounted associate, Aidite as well as the dilution of investment in Aoxin as a result of the 49% acquisition of Acumen Diagnostics Pte. Ltd. by Aoxin in October 2021. Aoxin is now a 32.95% equity-accounted associate of the Group.

Other assets as at 31 December 2021 decreased to \$7.1 million from \$8.6 million as at 31 December 2020. The decrease of \$1.5 million was mainly due to redemption of \$1.9 million redeemable preference shares held in trust in Aidite as a result of the disposal of the balance 12.3% of equity-accounted associate, Aidite off set by an increase in sign on bonus for dentists.

Other intangible assets as at 31 December 2021 increased to \$3.6 million from \$2.8 million as at 31 December 2020. The increase of \$0.8 million was mainly due to the cost of developing the Artificial Intelligence (AI) guided clinical decision support system.

### **Current Liabilities**

Trade and other payables as at 31 December 2021 increased to \$26.2 million from \$16.8 million as at 31 December 2020. The increase of \$9.4 million was mainly due to the increase of trade payables from the Covid-19 medical laboratory in Singapore as well as the dividends payable to non-controlling interest of the Group's 51% owned subsidiary, Acumen Diagnostics Pte. Ltd..

Other financial liabilities as at 31 December 2021 increased to \$3.6 million from \$1.9 million as at 31 December 2020. The increase of \$1.7 million was mainly due to the reclassification of \$3.0 million bank loan from non-current financial liabilities to current financial liabilities.

### **Non-Current Liabilities**

Other financial liabilities as at 31 December 2021 increased to \$80.2 million from \$75.5 million as at 31 December 200. The increase of \$4.7 million was mainly due to proceeds from new term loan of \$10.0 million offset by the redemption of redeemable preference shares held in trust in Aidite as well as the reclassification of \$3.0 million bank loan from non-current financial liabilities to current financial liabilities.

Lease liabilities from ROU assets as at 31 December 2021 increased to \$44.3 million from \$42.1 million as at 31 December 2020. The increase was mainly due to opening of new dental clinics in Singapore offset by the repayment of the operating lease and reclassification from non-current liabilities to current liabilities.



### **Statement of Cash Flows**

The Group generated net cash flow from operating activities of \$19.3 million in 4Q21. This was mainly derived from the profit generated from operations in 4Q21 and better control of working capital.

Net cash used in investing activities in 4Q21 amounted to \$6.7 million, mainly due to purchase of plant and equipment for the existing clinics and new dental clinics and acquisition of Acumen Research Laboratories Pte. Ltd. in October 2021.

Net cash used in financing activities in 4Q21 was \$14.5 million, mainly due to dividend payment to shareholders, share buyback exercise and repayment of lease liabilities arising from right-of use assets.

Consequent to the above factors, the Group's cash and cash equivalents was \$47.6 million as at 31 December 2021.

**3. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.**

No forecast had been issued for the current financial reporting period. The financial results are in line with the expectations as disclosed in previous quarterly announcement.

**4. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next reporting period and the next 12 months.**

### **Industry Prospects**

Barring any unforeseen circumstances and possible worsening of the Covid-19 situation in Singapore and Malaysia, there are no known significant changes in the trends and competitive conditions of the industry in which the Group operates and no other major known factors or events that may adversely affect the Group in the next reporting period and the next 12 months.

### **Recent Developments**

- Update on the Company's Singapore Operations

The Company has opened 15 new clinics in FY21. The Company has opened 1 new dental clinic in Sembawang Shopping Centre in January 2022 and another one in Jurong West is scheduled to commence operation in March 2022. The Company has also identified a location to start a free dental clinic, as its 100<sup>th</sup> clinic, to serve certain disadvantaged groups in the community. This is one way of giving back to society and is a major CSR exercise for the Group.

- Update on the Company's Malaysia Operations

The Company has opened 1 new dental clinic in Setia Alam, Kuala Lumpur. The Company has identified locations to open 4 new dental clinics in Selangor and Johor.



- Acumen Diagnostics Pte. Ltd.'s PCR Capabilities to Tackle Omicron Covid-19 Variant

On 3 December 2021, the Company's 51% subsidiary, Acumen Diagnostics Pte. Ltd. ("AD"), announced that its proprietary, locally-manufactured polymerase chain reaction ("PCR") test kits Acu-corona 2.0 and Acu-corona Duplex are able to detect Covid-19 positive cases infected with the Omicron variant.

- Acumen Diagnostics Pte. Ltd. Granted Ministry of Health Covid-19 Offsite PCR Testing license, up to 100 Sites Island-Wide

On 16 December 2021, AD announced that it has been granted a license by Ministry of Health, Singapore to provide offsite Covid-19 PCR swab services and serology sample collection. AD will roll out its testing services via the Group's network of clinics, and also at AD's headquarters located at The Gemini, 41 Science Park Road, Singapore. Currently, the Company has 46 clinics providing the testing services island-wide.

- Acumen Diagnostics Pte. Ltd. Appoints UOB Kay Hian Private Limited as Arranger to Explore NASDAQ Listing

On 17 January 2022, the Company announced that AD is exploring a proposed listing of its securities on the NASDAQ stock exchange in New York, USA. AD has appointed UOB Kay Hian Private Limited to assist AD with the listing evaluation and all relevant preparatory work including the selection of professional advisers and underwriting banks in relation to the proposed NASDAQ listing and fund raising exercise.

## **Future Plans**

The Group intends to continue executing the business plans outlined below.

- Expansion of network of dental clinics in Singapore and Malaysia

Currently, the Group operates 98 clinics in Singapore. The Group will be focusing on its operations in Singapore and has initiated a strategy of intensive organic growth of dental clinics in Singapore. It will expand its team of dentists to support the future growth of its operations in Singapore. We will continue to develop, invest and optimise our digital Artificial Intelligence (AI) guided clinical decision support system to provide the most effective and suitable treatment plans for patient. The Group believes it is well-positioned to cater to the rising demand for primary and high-value specialist dental healthcare services to its patients.

Currently, the Group operates 39 clinics in Malaysia. The clinics are 15 dental clinics in Johor, 19 dental clinics in Kuala Lumpur and 5 dental clinics in Malacca.

The Group intends to open at least 30 dental clinics a year from 2021 onwards in Singapore and Malaysia for the next 10 years. The eventual number of dental outlets will depend on available opportunities, pertinent market conditions and the evolving Covid-19 situation.



- Expansion into private dental healthcare market in the People’s Republic of China (“PRC”)

The main thrust of the Group’s proposed expansion in PRC is through organic growth to develop a new and sustainable growth pillar that can yield long term value for the Group.

- Expansion in Southeast Asia

The Group is continuously looking for opportunities to expand its dental business to Southeast Asian countries.

- Medical Laboratory

The Group will focus on rolling out its clinical testing laboratory pipeline of new tests including PCR assays for dengue sepsis and identification of bacterial pathogens and their associated antibiotics resistance in pneumonia and bloodstream infections.

## 5. Dividend

### (a) Current Financial Period Reported On

**Any dividend declared for the current financial period reported on? Yes**

Name of dividend	First Interim
Dividend Type	Cash
Dividend Amount per Share (in cents)	1.0 cent per ordinary share
Tax Rate	One Tier Tax Exempt

Name of dividend	Second Interim
Dividend Type	Cash
Dividend Amount per Share (in cents)	1.0 cent per ordinary share
Tax Rate	One Tier Tax Exempt

Name of dividend	Third Interim
Dividend Type	Cash
Dividend Amount per Share (in cents)	1.0 cent per ordinary share
Tax Rate	One Tier Tax Exempt

Name of dividend	Fourth Interim
Dividend Type	Cash
Dividend Amount per Share (in cents)	1.0 cent per ordinary share
Tax Rate	One Tier Tax Exempt



**(b) Corresponding Period of the immediately Preceding Financial Year**

**Any dividend declared for the corresponding period of the immediately preceding financial year? Yes**

Name of dividend	First Interim
Dividend Type	Cash
Dividend Amount per Share (in cents)	0.4 cent per ordinary share
Tax Rate	One Tier Tax Exempt

Name of dividend	Second Interim (Special)
Dividend Type	Cash
Dividend Amount per Share (in cents)	2.5 cent per ordinary share
Tax Rate	One Tier Tax Exempt

Name of dividend	Final
Dividend Type	Cash
Dividend Amount per Share (in cents)	0.5 cent per ordinary share
Tax Rate	One Tier Tax Exempt

**(c) The date the dividend is payable.**

Fourth Interim Dividend

The dividend will be paid on 24 March 2022.

**(d) Book closure date**

Fourth Interim Dividend

Notice is hereby given that Share Transfer Books and Register of Members of the Company will be closed on 9 March 2022 on which day no share transfer will be effected.

Duly completed and stamped transfers received by the Company's Share Registrar, Tricor Barbinder Share Registration Services (a division of Tricor Singapore Pte Ltd), 80 Robinson Road, #11-02 Singapore 068898, up to 5.00 p.m. on 8 March 2022 will be registered to determine members' entitlements to the interim dividend. Members (being depositors) whose securities account with The Central Depository (Pte) Limited are credited with ordinary shares in the capital of the Company as at 5.00 p.m. on 8 March 2022 will be entitled to the payment of the interim dividend.

**6. If no dividend has been declared (recommended), a statement to the effect.**

Not applicable.



**Part II – ADDITIONAL INFORMATION REQUIRED FOR FULL YEAR ANNOUNCEMENT**  
(This part is not applicable to Q1, Q2, Q3 or Half Year Results)

**7. Segment revenue and results for business or geographical segments (of the Group) in the form presented in the issuer’s most recently audited annual financial statements, with comparative information for the immediately preceding year.**  
**Business segments**

Please refer to Note 2 of Notes to the Condensed Interim Financial Statements.

**8. In the review of performance, the factors leading to any material changes in contributions to turnover and earnings by the business or geographical segments.**

**Performance by business segment**

The increase in primary healthcare segment revenue and result in FY21 as compared to FY20 was mainly due to higher revenue and result contribution from existing and new dental outlets in Singapore.

The increase in medical laboratory and dental equipment and supplies distribution segment revenue in FY21 as compared to FY20 was mainly due to higher revenue contribution from the Covid-19 medical laboratory.

**Performance by geographical segment**

The increase in the contribution to the Group’s revenue from Singapore operations in FY21 as compared to FY20 was mainly due to higher contribution from the existing and new dental clinics in Singapore as well as higher contribution from the Covid-19 medical laboratory.

The decrease in the contribution to the Group’s revenue from Malaysia operations in FY21 as compared to FY20 was mainly due to lower contribution from the dental equipment and supplies distribution company in Malaysia.

The decrease in the contribution to the Group’s revenue from PRC operations in FY21 as compared to FY20 was due to lower contribution from the dental clinic in Shanghai, PRC.

**9. A breakdown of sales**

		<b>Group</b>		
		<b>2021</b>	<b>2020</b>	<b>Change</b>
		<b>\$’000</b>	<b>\$’000</b>	<b>%</b>
9(a)	Revenue reported for first half	94,571	54,695	73
9(b)	Operating profit after tax before deducting non-controlling interests reported for first half year	21,477	8,867	142
9(c)	Revenue reported for second half	111,028	82,925	34
9(d)	Operating profit after tax before deducting non-controlling interests reported for second half year.	17,881	10,971	63



**10. A breakdown of the total annual dividend (in dollars value) for the issuer's latest full year and its previous full year.**

	<b>Latest Full Year \$'000</b>	<b>Previous Full Year \$'000</b>
Ordinary*	34,536	26,788
Preference	-	-
<b>Total</b>	<b>34,536</b>	<b>26,788</b>

\*Total annual dividend for FY21 comprises recommended FY21 fourth interim dividend (from FY21Q4 profit and retain earnings) of \$9.40 million, third interim dividend of \$9.40 million (from FY21Q3), second interim dividend of \$7.87 million (from FY21Q2), and \$7.87 million first interim dividend paid in respect of FY21Q1 profit.

\*Total annual dividend for FY20 comprises recommended FY20 final dividend (from FY20H2 profit) of \$3.94 million and second interim dividend of \$19.68 million, and \$3.17 million interim dividend paid in respect of FY20H1 profit.

**11. If the Group has obtained a general mandate from shareholders for Interested Parties Transactions (IPTs), the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to the effect.**

The Group did not obtain a general mandate from shareholders for IPTs.

**12. Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(13) in the format below. If there are no such persons, the issuer must make an appropriate negative statement.**

Name	Age	Family relationship with any director, chief executive officer and/or substantial shareholder	Current position and duties, and the year the position was held	Details of changes in duties and position held, if any, during the year
Foo Siew Jiu	53	Wife of Dr Ng Chin Siau, Group Chief Executive Officer of Q & M Dental Group (Singapore) Limited ("QDGS").	General Manager (1999)	None
Ng Sook Hwa	50	Sister-in-law of Ng Sook Hwa, Group Financial Controller of QDGS. Sister of Dr Ng Chin Siau, Group Chief Executive Officer of QDGS.	Group Financial Controller (June 2011)	None



**Q & M Dental Group (Singapore) Limited**  
(Incorporated in the Republic of Singapore)  
(Company Registration No: 200800507R)

**13. Confirmation pursuant to Rule 720 (1) of the Listing Manual**

The Company hereby confirms that it has procured undertakings from all its directors and executive officers under Rule 720 (1) of the Listing Manual.

**14. Confirmation by the Board pursuant to Rule 705 (5) of the Listing Manual**

On behalf of the Board of Directors of the Company, we, the undersigned directors, do hereby confirm that, to the best of our knowledge, nothing has come to the attention of the Board of Directors of the Company that may render the condensed interim financial statements to be false or misleading in any material aspect.

**On behalf of the Board of Directors**

**Dr Ng Chin Siau**  
Group CEO & Executive Director

**Dr Ang Ee Peng Raymond**  
COO & Executive Director

**23 February 2022**